Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company’s products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, Nano, DNAxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company provides integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production and scale up; assay development services; circulating tumor cell and DNA; germline genetic DNA; and FFPE tumor tissue DNA services. It serves academic, research institutions, and pharmaceutical factories. Abnova (Taiwan) Corporation was founded in 2002 and is headquartered in Taipei, Taiwan.
तुलना करने के लिए मीट्रिक्स | 4133 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4133पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −1,194.1x | 11.3x | −0.4x | |
PEG अनुपात | 11.71 | 0.05 | 0.00 | |
क़ीमत/बुक | 1.1x | 1.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 3.9x | 3.0x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 40.9% | 50.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 16.2% | 6.6% | अनलॉक करें |